A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
about
A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.
description
2017 nî lūn-bûn
@nan
2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
name
A safety analysis of edaravone ...... d, placebo-controlled studies.
@en
A safety analysis of edaravone ...... d, placebo-controlled studies.
@nl
type
label
A safety analysis of edaravone ...... d, placebo-controlled studies.
@en
A safety analysis of edaravone ...... d, placebo-controlled studies.
@nl
prefLabel
A safety analysis of edaravone ...... d, placebo-controlled studies.
@en
A safety analysis of edaravone ...... d, placebo-controlled studies.
@nl
P2093
P2860
P921
P1476
A safety analysis of edaravone ...... d, placebo-controlled studies.
@en
P2093
Alexander Kalin
Elvia Medina-Paraiso
Kaoru Ishizaki
Masahiko Wasaki
Takanori Saita
Yannong Zhang
P2860
P356
10.1080/21678421.2017.1362440
P577
2017-10-01T00:00:00Z